Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haploidentical Bone Marrow Transplant with CTLA4-Ig Ex Vivo Treatment for Hematologic Cancers
NCT00005854Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Dec 1999
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abatacept in hematologic malignancy, sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Incidence and severity of acute graft versus host disease. Started Dec 1999; status: completed.
02
Drugs
abatacept
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT00005854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005854.